Contract Development and Manufacturing Organizations (CDMO)
Strategic Profile
With over 50 facilities on four continents, Catalent has supported more than half the products approved by the Food and Drug Administration in the last ten years and annually produces 70 billion doses for 8,000 products. The company derives its revenues primarily from long-term supply agreements with pharmaceutical customers.
Cyborg Score Rationale
Market-leading CDMO with dominant FDA approval support, extensive global capacity, and scale ($4.42B TTM revenue). Strategic backing by Novo Holdings and expanding cell/gene therapy capabilities support growth. Transition to private ownership provides operational flexibility but reduces trading liquidity.
Top Insights
Market leader in CDMO services supporting >50% of recent FDA approvals with 70B+ annual doses produced
Operates 50+ facilities across four continents with diversified revenue from oral, biologics, and specialty delivery segments
Strategic partnership with Novo Nordisk expanding manufacturing capacity from 2026 onwards for GLP-1 drug filling
Expanding cell and gene therapy manufacturing capabilities through partnerships (GelMEDIX in March 2026, Cartherics in April 2026)
Named Competitors
CDMO Services — Leading global CDMO with biologics and cell therapy focus